Neutral Biocon; target of Rs 400: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 400 in its research report dated October 23, 2020.

Buy Biocon; target of Rs 495: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 495 in its research report dated October 23, 2020.

Buy Biocon; target of Rs 500: ICICI Direct

ICICI Direct is bullish on Biocon recommended buy rating on the stock with a target price of Rs 500 in its research report dated October 23, 2020.

Biocon Consolidated September 2020 Net Sales at Rs 1,744.80 crore, up 10.98% Y-o-Y

Biocon Standalone September 2020 Net Sales at Rs 560.00 crore, up 6.89% Y-o-Y

Biocon Consolidated September 2020 Net Sales at Rs 1,744.80 crore, up 10.98% Y-o-Y

Biocon Standalone September 2020 Net Sales at Rs 560.00 crore, up 6.89% Y-o-Y

Kiran Mazumdar Shaw says COVID-19 vaccine may be available by June 2021

Shaw says vaccine candidates will first be approved for emergency use and full approval will come only after evaluating the durability of response.

SEBI levies fine on Biocon employee for violating insider trading norms

The employee, Vandana Singh (noticee), general manager regulatory affair of Biocon at the time of investigation and also a designated person, is facing a fine of Rs 3 lakh for violating provisions of Prohibition of Insider Trading (PIT) norms.

Biocon Q2 net profit down 23% at Rs 195 crore

It had posted a net profit of Rs 253.8 crore for the July-September quarter previous fiscal, Biocon said in a late-night BSE filing on Thursday.

Exclusive | Goldman Sachs Private Equity in talks to buy minority stake in IPO-bound Biocon Biologics

If the deal — which may value the firm in excess of $3.5 billion — fructifies, it would mark the third successive investment in 2020 for Kiran Mazumdar Shaw-led Biocon Biologics

Cadila: a formidable play in Covid times and beyond

Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

Biocon shares jump 5% on launch of diabetes drug in US

As per a regulatory filing on BSE, Biocon Biologics India, a subsidiary of Biocon, and Mylan N.V., announced the US launch of Semglee.

Nifty may move towards 11,500; these three bets could give up to 16% returns

Technically we believe the index is expected to swing above the upper bound of the 'Broadening formation (11,377)' & move towards 11,500 zone swiftly.

Kiran Mazumdar Shaw of Biocon tests positive for COVID-19

Biocon is one of the companies looking to create a vaccine to fight COVID-19

Aim to list Biocon Biologics on capital markets by 2023: CFO MB Chinappa

Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.

Tata Capital to invest Rs 225 crore in Biocon Biologics for minority stake

The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion

Neutral Biocon; target of Rs 450: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 450 in its research report dated July 25, 2020.

Biocon share price falls 3% after Health Ministry gives a pass to its COVID-19 drug

A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19, sources said.

Pharma: Trump’s executive orders may possibly provide better market access opportunities

Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare

Health ministry decides against including Itolizumab in clinical management protocol for COVID-19

Considering the unmet medical needs in COVID-19, Itolizumab, an already approved drug of Biocon used for treating psoriasis, was approved for "restricted emergency use" in the treatment of coronavirus by the DCGI recently.

Buy Biocon; target of Rs 490: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 490 in its research report dated July 24, 2020.

Biocon Consolidated June 2020 Net Sales at Rs 1,671.30 crore, up 14.01% Y-o-Y

Biocon Standalone June 2020 Net Sales at Rs 520.70 crore, up 8.3% Y-o-Y

Biocon share price falls 2% on June quarter numbers

The company's revenue from operations rose 15 percent to Rs 1,671 crore versus Rs 1,459 crore.